Tempest Therapeutics, Inc. Payments for Restructuring
Tempest Therapeutics, Inc. (TPST) reported Payments for Restructuring of $1.84 million for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2018-11-09
- Tempest Therapeutics, Inc. payments for restructuring for the quarter ending 2018-09-30 was $531.00K, a 66.48% decline year-over-year.
- Tempest Therapeutics, Inc. payments for restructuring for the quarter ending 2018-06-30 was $555.00K, a 70.82% decline year-over-year.
- Tempest Therapeutics, Inc. payments for restructuring for the quarter ending 2018-03-31 was $756.00K, a 65.76% decline year-over-year.
- Tempest Therapeutics, Inc. payments for restructuring for the quarter ending 2017-12-31 was $857.00K.
- Tempest Therapeutics, Inc. payments for restructuring for fiscal 2017 was $6.55M.
- Tempest Therapeutics, Inc. payments for restructuring for fiscal 2016 was $0.00.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 6 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|---|
| 2018-09-30 | $531.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.09M derived: sum of 2 quarters · filed 2018-11-09 | $1.84M 10-Q · filed 2018-11-09 | $2.70M derived: sum of 4 quarters · filed 2018-11-09 |
| 2018-06-30 | $555.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.31M 10-Q · filed 2018-08-09 | $2.17M derived: sum of 3 quarters · filed 2018-08-09 | $3.75M derived: sum of 4 quarters · filed 2018-08-09 |
| 2018-03-31 | $756.00K 10-Q · filed 2018-05-03 | $1.61M derived: sum of 2 quarters · filed 2018-05-03 | $3.20M derived: sum of 3 quarters · filed 2018-05-03 | $5.10M derived: sum of 4 quarters · filed 2018-05-03 |
| 2017-12-31 | $857.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $2.44M derived: sum of 2 quarters · filed 2018-03-15 | $4.34M derived: sum of 3 quarters · filed 2018-03-15 | $6.55M 10-K · filed 2018-03-15 |
| 2017-09-30 | $1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $3.49M derived: sum of 2 quarters · filed 2017-11-02 | $5.69M 10-Q · filed 2017-11-02 | |
| 2017-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $4.11M 10-Q · filed 2017-08-03 | ||
| 2017-03-31 | $2.21M 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |